Showing results (1061-1070 of 5,983) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|April 2, 2014
Targeting multiple key signaling pathways in melanoma using leelamineRaghavendra Gowda, SubbaRao V Madhunapantula, Omer F Kuzu, et al.
Molecular Cancer Therapeutics|April 8, 2014
UPARANT: a urokinase receptor-derived peptide inhibitor of VEGF-driven angiogenesis with enhanced stability and in vitro and in vivo potencyMaria Vincenza Carriero, Katia Bifulco, Michele Minopoli, et al.
Molecular Cancer Therapeutics|March 29, 2014
Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growthQiang Wu, Manish Kohli, H Robert Bergen, et al.
Molecular Cancer Therapeutics|March 18, 2014
Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancerToni M Brand, Mari Iida, Emily F Dunn, et al.
Molecular Cancer Therapeutics|March 18, 2014
ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer modelsLi Zhang, Carla Castanaro, Bo Luan, et al.
Molecular Cancer Therapeutics|March 18, 2014
Protein kinase d as a potential chemotherapeutic target for colorectal cancerNing Wei, Edward Chu, Peter Wipf, et al.
Molecular Cancer Therapeutics|March 25, 2017
Lectin, Galactoside-Binding Soluble 3 Binding Protein Promotes 17-N-Allylamino-17-demethoxygeldanamycin Resistance through PI3K/Akt Pathway in Lung Cancer Cell LineJong Kyu Woo, Jeong-Eun Jang, Ju-Hee Kang, et al.
Molecular Cancer Therapeutics|November 23, 2012
miR-148b functions as a tumor suppressor in pancreatic cancer by targeting AMPKα1Gang Zhao, Jun-Gang Zhang, Yang Liu, et al.
Molecular Cancer Therapeutics|March 21, 2013
Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancerMichael A Batey, Yan Zhao, Suzanne Kyle, et al.
Molecular Cancer Therapeutics|March 22, 2013
Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal diseaseLai-Ping Zhong, Dong-Wang Zhu, William N William, et al.
Pageof 599